These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25260377)

  • 21. [Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy].
    Quintin K; Créhange G; Graff P
    Cancer Radiother; 2024 Aug; 28(4):333-340. PubMed ID: 39155168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
    Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy.
    McDonald AM; Baker CB; Popple RA; Shekar K; Yang ES; Jacob R; Cardan R; Kim RY; Fiveash JB
    Radiat Oncol; 2014 Jun; 9():129. PubMed ID: 24893842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.
    Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients.
    Vapiwala N; Wong JK; Handorf E; Paly J; Grewal A; Tendulkar R; Godfrey D; Carpenter D; Mendenhall NP; Henderson RH; Stish BJ; Vargas C; Salama JK; Davis BJ; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1082-1089. PubMed ID: 33539968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.
    Katayama S; Striecker T; Kessel K; Sterzing F; Habl G; Edler L; Debus J; Herfarth K
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):926-33. PubMed ID: 25216858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.
    Tamihardja J; Schortmann M; Lawrenz I; Weick S; Bratengeier K; Flentje M; Guckenberger M; Polat B
    Strahlenther Onkol; 2021 Feb; 197(2):124-132. PubMed ID: 32833036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
    Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.
    Lips IM; Dehnad H; van Gils CH; Boeken Kruger AE; van der Heide UA; van Vulpen M
    Radiat Oncol; 2008 May; 3():15. PubMed ID: 18495016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
    Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
    Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786).
    Vigneault E; Morton G; Parulekar WR; Niazi TM; Springer CW; Barkati M; Chung P; Koll W; Kamran A; Monreal M; Ding K; Loblaw A
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):527-533. PubMed ID: 29903505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer.
    Ghadjar P; Gwerder N; Manser P; Vock J; Madlung A; Mini R; Aebersold DM
    Strahlenther Onkol; 2010 Dec; 186(12):687-92. PubMed ID: 21136028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome.
    Fonteyne V; Lumen N; Ost P; Van Praet C; Vandecasteele K; De Gersem Ir W; Villeirs G; De Neve W; Decaestecker K; De Meerleer G
    Radiother Oncol; 2013 Nov; 109(2):229-34. PubMed ID: 24016677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer.
    Lopez Guerra JL; Isa N; Matute R; Russo M; Puebla F; Kim MM; Sanchez-Reyes A; Beltran C; Jaen J; Bourgier C; Marsiglia H
    Clin Transl Oncol; 2013 Apr; 15(4):271-7. PubMed ID: 22855189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant.
    Eade TN; Horwitz EM; Ruth K; Buyyounouski MK; D'Ambrosio DJ; Feigenberg SJ; Chen DY; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):338-45. PubMed ID: 18207665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.